Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2001
02/21/2001CN1062311C Fused gene of IL-2 derivatives and ANP derivatives, protein products and their application thereof
02/21/2001CN1062162C External use ointment for treatment of cutaneous pigmentation
02/20/2001US6191282 Derivatives of 5-membered nitrogen containing heterocyclic ring is used as anticarcinogenic agent and anticoagulant
02/20/2001US6191269 Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
02/20/2001US6191261 Immunoglobulin that preferential binds a growth factor; for the diagnosis and treatment of cell proliferative defects; antiproliferative agents
02/20/2001US6191260 Brain-associated inhibitor of tissue-type plasminogen activator
02/20/2001US6191257 Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy
02/20/2001US6191255 Isolated matrix metalloproteinase of given amino acid sequence having the activation capability of pro-matrix metalloproteinase 2; vectors; transformed cells; use in diagnosis of cancer
02/20/2001US6191254 Of given amino acid sequences
02/20/2001US6191172 Used in drugs and cosmetics
02/20/2001US6191169 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
02/20/2001US6191166 Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
02/20/2001US6191156 Compositions and methods for treating bladder dysfunction
02/20/2001US6191139 Antidepressant
02/20/2001US6191115 Peptides and polypeptides
02/20/2001US6191114 Immunological activity for a peptide of the limulus anti-LPS factor
02/20/2001US6191113 Peptide for inhibiting growth of smooth muscle cells
02/20/2001US6191112 Human therapeutic uses of BPI protein products
02/20/2001US6191110 Promoting wound healing in mammals with peptides
02/20/2001US6191109 Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
02/20/2001US6191108 RH blood group antigen compositions and methods of use
02/20/2001US6191107 Complexes with biodregadable polymers
02/20/2001US6191106 Muteins of epidermal growth factor exhibiting enhanced binding at low pH
02/20/2001US6191105 Insulin free compositions with insulin-methyl(ethylene glycol)-o-hexanoic acid conjugate and composition with water in oil microemulsion
02/20/2001US6191104 Methods of treating graft rejection with the IL-17 receptor
02/20/2001US6191103 Inhibitors of protein band iii ligand
02/20/2001US6191102 Glucagon like peptide
02/20/2001US6190912 Nucleotide sequences coding modulator of cell killing; for the treatment of cell proliferation defects
02/20/2001US6190909 TH2-specific gene
02/20/2001US6190901 Chicken interleukin-15 and uses thereof
02/20/2001US6190897 Nucleotide sequence coding hydrolase; for use in digestion of animal feeds
02/20/2001US6190894 Method and compositions for disrupting the epithelial barrier function
02/20/2001US6190887 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein
02/20/2001US6190884 Transforming host cell with polynucleotide which encodes the growth factor of defined amino acid sequence, and culturing for gene expression
02/20/2001US6190881 Polynucleotide; recombinant production; drug screening of bactericides and enzyme inhibitors
02/20/2001US6190880 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
02/20/2001US6190875 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
02/20/2001US6190873 Mixing in aqueous medium the sample, a cyclosporin-label conjugate having specific linking groups, and antibodies capable of binding to cyclosporin-label conjugate; and determining presence of complex
02/20/2001US6190871 Determining efficacy of monoclonal antibody to neutralize primary isolates by culturing various concentrations of antibody with virus and h9 cells, determining concentration of p24 antigen as indicator of infection, and comparing
02/20/2001US6190869 Antisense inhibition of protein kinase C-theta expression
02/20/2001US6190866 Selecting bacterial target gene, preparing peptide nucleic acid having region complementary to target, identifying active peptide nucleic acid, contacting bacteria with active compounds, and determining effect on bacteria; bactericides
02/20/2001US6190864 HCV genomic sequences for diagnostics and therapeutics
02/20/2001US6190863 Immunoglobulin m which recognizes gangioside gm2 which appears on human immunodeficiency virus infected t-cells; viricides; causes complement-mediated cytolysis in humans
02/20/2001US6190723 Neutralization of food allergens by thioredoxin
02/20/2001US6190663 Human MAP kinase homolog
02/20/2001US6190662 Materials and methods relating to the attachment and display of substances on cell surfaces
02/20/2001US6190658 Genetically modified manganese superoxide dismutase for treating oxidative damage
02/20/2001US6190656 Activating mammalian immune system entails series of il-2 administrations that are effected intermittently over an extended period; each administration of il-2 is sufficient to allow spontaneous dna synthesis; measuring dna synthesis
02/20/2001US6190655 Methods of using Flt-3 ligand for exogenous gene transfer
02/20/2001US6190640 Administering indium radiolabelled humanized monoclonal antibody or a in radiolabelled binding fragment of a humanized monoclonal antibody which binds to antigen a33 which is presented on surfaces of cells of cancer carcinoma
02/20/2001CA2513033A1 Cosmetic use of botulinum toxin for treatment of downturned mouth
02/20/2001CA2302629C Estrogen receptor
02/20/2001CA2225412C A peptide inhibiting elevations of triglyceride levels in blood and an agent for inhibiting elevations of triglyceride levels in blood comprising the peptide as an active component
02/20/2001CA2199403C Novel pka-binding proteins and uses thereof
02/20/2001CA2197233C Methods of identifying compounds useful for treating autoimmune diseases
02/20/2001CA2158991C Adipocyte differentiation inhibiting peptide and adipocyte differentiation inhibiting agent using the peptide as active component thereof
02/20/2001CA2125037C Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
02/20/2001CA2110797C Modified sialyl lewis x compounds
02/20/2001CA2076749C Vasoactive vasotocin derivatives
02/20/2001CA2072658C Use of honey as vaccine
02/20/2001CA2060208C Wound healing
02/20/2001CA2043536C Tumor cell growth inhibitor
02/20/2001CA1341185C Intercellular adhesion molecules and their binding ligands
02/20/2001CA1341182C Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
02/15/2001WO2001011369A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
02/15/2001WO2001011335A2 Antiviral compounds that inhibit viral replication
02/15/2001WO2001011085A2 Bdnf polymorphism and association with bipolar disorder
02/15/2001WO2001011067A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof
02/15/2001WO2001011064A2 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy
02/15/2001WO2001011063A2 Gene transfer combination vectors, method for the production and utilization thereof
02/15/2001WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
02/15/2001WO2001011049A2 Methods and compositions concerning canine interleukin 5
02/15/2001WO2001011048A2 Therapeutic polypeptides and methods for using same
02/15/2001WO2001011047A2 Dna sequences isolated from human colonic epithelial cells
02/15/2001WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule
02/15/2001WO2001011044A1 Tumor antigen
02/15/2001WO2001011043A1 Single-chain polypeptides comprising troponin i n-terminal fragments and troponin c
02/15/2001WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY
02/15/2001WO2001011038A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
02/15/2001WO2001011031A2 Gene transfer to pancreatic beta cells for prevention of islet dysfunction
02/15/2001WO2001011028A1 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof
02/15/2001WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes
02/15/2001WO2001011022A1 Mouse g-protein coupled receptor edg3
02/15/2001WO2001011013A2 The interaction of smad6 with hox proteins and uses thereof
02/15/2001WO2001011012A2 Human melanoma h11 gene polynucleotides, polypeptides, and methods of use
02/15/2001WO2001010912A1 Multiple cytokine-antibody complexes
02/15/2001WO2001010907A2 Therapeutic polypeptides and methods for using same
02/15/2001WO2001010904A1 Map
02/15/2001WO2001010903A2 Proteases and protease inhibitors
02/15/2001WO2001010902A2 Nucleoc acids and secreted polypeptides encoded thereby
02/15/2001WO2001010901A2 Antimicrobial histone h1 compositions, kits, and methods of use thereof
02/15/2001WO2001010900A2 Globular assembly of amyloid beta protein and uses thereof
02/15/2001WO2001010899A2 Treatment of liver disease and injury with cxc chemokines
02/15/2001WO2001010898A2 Compositions and methods for regulating the cell cycle and other cellular processes involving the tgf-beta family
02/15/2001WO2001010895A1 Streptogramin derivatives, production thereof and compositions containing the same
02/15/2001WO2001010894A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
02/15/2001WO2001010893A2 Il-16 antagonists
02/15/2001WO2001010892A2 Peptide antagonists of factor viia
02/15/2001WO2001010891A2 Il-16 antagonists
02/15/2001WO2001010889A1 Rat-g-protein coupled receptor brs3